We read with interest the recent report by Mehta et al 1 in which the authors concluded that relapse rates and eventfree survival in patients with acute myeloid leukemia (AML) in first remission were superior after ABO-incompatible compared with ABO-compatible HLA-matched related donor bone marrow transplantation (actuarial 5-year probability of relapse, 12% vs 33%; P = 0.028). Their conclusions were based upon retrospective analysis of data from 119 patients conditioned with cyclophosphamide (n = 72) or melphalan (n = 47) combined with total body irradiation (TBI). Seventy-six patients received ABOmatched, and 43 patients received ABO-mismatched transplants (major ABO-mismatch, n = 16; minor and bidirectional ABO mismatches, n = 27). We believe that the authors' conclusions are not sufficiently supported by their data and would like to point out several limitations of their study.
First, the significance of their observation disappeared when ABO-incompatible transplants were analyzed according to the directions of the ABO mismatches (major vs minor). The authors interpreted this to suggest a loss of statistical power due to the small sample sizes. They do not comment, however, on the possibility that their apparent association might be due to chance which seems likely given that their findings are not in keeping with results from other studies in which improved relapse-free survival was not detected after ABO-incompatible as compared to ABOcompatible marrow transplantation for AML. [2] [3] [4] [5] [6] [7] Only one group of investigators associated minor and major ABO incompatibility with increased transplant-related mortality resulting from organ toxicity and sepsis possibly due to use of non plasma-depleted platelet products. 8 Kalaycioglu et al 5 reported that minor and major ABO incompatibility was associated with an improved overall survival in patients with CML (n = 99) but not in those with AML/MDS (n = 100) after marrow transplantation from HLA-identical related donors using a non-TBI containing preparative regimen.
We recently analyzed outcomes of 921 patients with hematologic malignancies transplanted between 1983 and 1998 at the Fred Hutchinson Cancer Research Center in Seattle from HLA-identical related donors after myeloablative conditioning.
2 GVHD prophylaxis consisted of cyclosporine and methotrexate in all patients. One hundred and fifty patients (16%) received major ABO-mismatched, 116 patients (13%) minor ABO-mismatched, and 30 patients (3%) major/minor ABO-mismatched transplants. Transplants were performed for AML in 211 patients (23%), and for MDS in 82 patients (9%). In this relatively homogeneous patient population, presence of minor, major or bidirectional ABO incompatibilities did not affect outcome, and mismatching was not associated with decreased relapse rates or improved survival among all patients and in those with AML/MDS. Mehta et al further speculate that 'immune reactions associated with ABO-mismatched transplants may have direct anti-leukemic effects' which, if true, should preferentially be operative in host-directed (minor ABO-mismatched) rather than donor-directed (major ABOmismatched) transplants.
Second, AML disease risk stratification according to FAB subtypes was insufficient in the study by Mehta et al The authors grouped patients according to FAB M1-M3 vs M0/M4-M7 subtypes. Inclusion of patients with the favorable FAB M3 subtype 9 with M1 and M2 patients, however, may obscure important prognostic information, and a skewed distribution of patients with FAB M3 subtype between ABO-matched and ABO-mismatched transplants might influence relapse rates. Furthermore, the proportion of patients for whom no information with regard to their FAB subtype was available was considerably different between ABO-matched and ABO-mismatched transplant recipients (18% vs 9%).
In conclusion, most studies published to date suggest no differences in outcome after ABO-incompatible as compared to ABO-compatible allogeneic transplantation. Given the hemolytic complications possibly associated with ABOincompatible transplants, an ABO-compatible donor would appear preferable over an incompatible donor also for patients with AML undergoing allogeneic bone marrow transplantation.
M Mielcarek
Fred We thank Mielcarek et al for pointing out possible limitations of our study; most of which in fact we had acknowledged in the paper: 1 'This observation has been made in a relatively small group of patients and needs to be validated. It is not known if this observation holds true for other diagnoses, disease stages, alternative donors or PBSCT', and 'With the conflicting data in the literature, it is clear that further work is necessary to determine the effects of ABO incompatibility on the outcome of relatively homogeneous groups of patients allografted using marrow'.
The P values shown in Table 3 represented overall comparisons of ABO-matched, minor mismatched and major mismatched groups (P = 0.086 for relapse). When the minor and major mismatched groups were compared separately with the matched group, the difference in relapse rates was significant for minor/bidirectional mismatches (P = 0.051), but not for major (P = 0.22) -which is in keeping with the graft-versus-host direction isohemagglutinins seen in minor/bidirectional mismatches.
The disparate distribution of unknown FAB subtypes between ABO matched (14 of 76; 18%) and mismatched (4 of 43; 9%) was not statistically significant (P = 0.29; Fisher's exact test). Similarly, the distribution of M3 FAB subtypes between ABO matched (6 of 76; 8%) and mismatched (6 of 43; 14%) was not statistically significant (P = 0.29; 2 test). Relapse rates were higher in the ABO matched group after the exclusion of all patients with unknown FAB subtypes (P = 0.01), M3 FAB subtypes (P = 0.081), or both (P = 0.036).
There are some possible explanations for the differences between our study and that of Mielcarek et al. 2 Their study included 211 patients with AML who were allografted from HLA-matched relatives. 2 The stage at allograft was not specified -and presumably included patients other than those in first CR. Similarly, no FAB subtype or karyotype information was provided. Additionally, no doubt patients conditioned with very high intensity regimens with significantly lower relapse rates 3 were also included. A skewed distribution of any of these characteristics could easily have obscured any effect of ABO mismatch on outcome in their limited analysis.
In our opinion, further work is required to address effect of ABO incompatibility on the outcome of allogeneic transplantation.
J Mehta
Division 
